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Despite major advances in the understanding of mecha- 
nisms, better diagnostic methods and a wide array of new 
modes of therapy, management of cardiac arrhythmias 
continues to be a challenge. Because of possible deleterious 
effects of antiarrbythmic therapy, the decision about when 
and how to treat should be weighed carefully with emphasis 
on symptoms and the prognostic significance of the arrbyth- 
mia. When possible, the high risk patient should be re- 
ferred to a center where expertise and diagnostic and 
therapeutic possibilities allow optimal treatment. 
(J Am Co11 Cardiol1989;14:1417-28) 
Cardiac “arrhythmology” has seen major changes during 
the last 40 years. The introduction of several new tech- 
niques has contributed to better understanding of the mech- 
anism, site of origin, prognosis and treatment of arrhythmias. 
the atria. In principle, the same holds for any type of 
supraventricular or ventricular arrhythmia. 
Clinical factors. Figure 1 illustrates the many factors that 
play a role in the occurrence of an arrhythmia and how they 
These developments have improved the care are interrelated. Some of these factors are 
of patients, but the wide range of possible diag- 1 ,k+( 1 c : ‘c : present over a long period of time-for example, 
nostic techniques and treatment modes has in- - - - - - . . . ?? . 
c 
the degree of vessel narrowing in chronic coro- 
creased the risk of overtreatment or even mal- * * * nary artery disease or an increased or decreased 
treatment and unnecessary cost. What, then, is 1 ’ 
. *& 
. 
‘0 
. amount of heart muscle as in ventricular hyper- 
needed to know when, how and where to treat an 
‘m 
. trophy or after an old myocardial infarction. 
arrhythmia successfully, safely and cost effec- Other factors are dynamic-for example, 
tively? We have listed those requirements in 
ANNIVERSARY 
changes in platelet function, degree of ischemia, 
Table 1 and will discuss these in more detail in the neurophysiologic system and so forth. 
this review. 
1 ‘3 4 9 
Relation Between Pump Function, Blood 
Supply, Neurocontrol and Cardiac Rhythm 
It is a mistake to prescribe antiarrhythmic medication 
without realizing that abnormalities of pump function, blood 
supply or neurocontrol of the heart may be totally or 
partially responsible for a cardiac arrhythmia. Most physi- 
cians know that atria1 fibrillation is a rare arrhythmia in the 
healthy heart and that proper treatment requires a careful 
evaluation to identify, and when possible correct, causes like 
cardiac muscle stretch, ischemia, inflammation, fibrosis, 
infiltration. intoxication or abnormalities in neurocontrol of 
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The finding of a cardiac arrhythmia should 
always be a stimulus for careful history taking and an 
appropriate physical examination. These should be followed 
by suitable noninvasive and invasive studies in search of 
indications for heart disease. The discovery of ventricular 
premature beats in a patient after a myocardial infarction 
should first be a stimulus to rule out (and when present, 
treat!) ischemia outside the infarcted area and disturbances 
of pump function rather than a cue to prescribe antiarrhyth- 
mic medication. 
A good arrhythmologist shouldfirst be a good clinician! 
He or she should not only identify (and possibly correct) 
This article is part of a series of articles celebrating 
the 40th anniversary of the American College of 
Cardiology. The series attempts to set the stage for the 
future by describing current state of the art manage- 
ment of selected major cardiovascular problems and 
the basic knowledge that will provide directions for 
advances in diagnosis and therapy. 
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Table 1. Requirements for the Cardiologist Treating Arrhythmias 
1. 
2. 
3. 
4. 
5. 
Understanding of the relation between pump function, blood supply, 
neurocontrol and rhythm of the heart. 
Knowledge of the different types of cardiac arrhythmias, their site of 
origin, electrocardiographic diagnosis, mechanism and importance of 
their etiology. 
Knowledge of when to treat and understanding of the value and 
limitations of the different diagnostic techniques. 
Understanding risk stratification of arrhythmias. 
Knowledge of the value, limitations and costs of the different 
therapeutic options. 
static contributing factors but also control (as far as possible) 
dynamic changes. 
Different Types of Cardiac Arrhythmias, 
Their Site of Origin, Electrocardiographic 
Diagnosis, Mechanism and the Importance 
of Their Etiology 
Observations in the tissue bath, the isolated and intact 
animal heart and the human heart have resulted in a better 
understanding of the possible mechanisms of cardiac ar- 
rhythmias (l-6). Programmed electrical stimulation of the 
heart combined with the recordings of local endocardial and 
epicardial electrical activity frequently allows us to localize 
the site of origin or pathway of the arrhythmia in the intact 
human heart (7-11). Careful evaluation of the 12 lead elec- 
trocardiogram (ECG) during the arrhythmia at the time of 
programmed electrical stimulation and cardiac activation 
mapping has resulted in the recognition of specific ECG 
patterns. This has made it possible to distinguish among the 
different types of supraventricular tachycardia, to locate the 
site of atrioventricular (AV) block, the site of origin of a 
ventricular tachycardia and the ventricular and atria1 end of 
an accessory AV pathway and to differentiate between a 
supraventricular and a ventricular origin of a wide QRS 
tachycardia (12-26). A review of these advances has recently 
been published elsewhere (27). 
Mechanism of reentry. The observation that most clini- 
cally occurring regular sustained tachycardias can reproduc- 
ibly be initiated and terminated by timed extrastimuli during 
programmed electrical stimulation suggests that reentry is 
the most common mechanism of these arrhythmias. How- 
ever, proof that reentry is the tachycardia mechanism can 
only be provided by delineating the pathway and demon- 
strating that the arrhythmia can be terminated temporarily 
by creating refractoriness in a part of the circuit and defini- 
tively by (surgical, electrical or chemical) ablation of part of 
the pathway. 
Other arrhythmogenic mechanisms: early and late afterde- 
polarizations. In recent years, increasing attention has been 
given to other arrhythmogenic mechanisms that may play a 
role in clinically occurring arrhythmias. In isolated tissue, 
early and late afterdepolarizations have been shown to lead 
to arrhythmias (6). Early afterdepolarizations, which can be 
produced experimentally by barium, hypoxia, high concen- 
tration of cathecholamines, sotalol, N-acetyl procainamide 
and cesium (6), have been suggested as a cause of torsade de 
pointes in patients with the congenital or acquired long QT 
syndrome (28,29). Late afterdepolarizations can be induced 
experimentally by digitalis and seem to be responsible for 
some clinical arrhythmias occurring in digitalis intoxication 
(30). Arrhythmogenic mechanisms based on afterdepolariza- 
tions and their possible clinical implications were recently 
discussed by Zipes (2). Unfortunately, intracellular record- 
ings are not possible in the intact human heart, making the 
study of the relevance of these mechanisms to human 
arrhythmias extremely difficult. A possible solution might be 
the development of drugs specifically counteracting early or 
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Figure 1. Model showing the factors that play a 
role in cardiac arrhythmias. The basic triangle 
consists of electrical instability, hemodynamic 
,~~~~~~~~~A~oRs dysfunction and ischemia. Each of these three cornerstones has static and dynamic compo- nents. Modulating (MOD.) factors include the autonomic nervous system, electrolytes, hor- mones and drugs. COND = conduction. 
am 
4 _) 
COND.VELOCITY REFRACTORINESS 
JACC Vol. 14, No. 6 
November 15. 1989:1417-28 
WELLENS AND BRUGADA 1419 
TREATMENT OF CARDIAC ARRHYTHMIAS 
Table 2. Relation Between Etiology of Ventricular TachycardiaNentricular Fibrillation (VTIVF) 
and Arrhythmia Recurrence and Death During Follow-Up 
Old MI 
SMVT 
RVD Idiopathic 
VF SMVT SMVT VF 
Total no. of patients 79 31 II 52 6 
Total deaths I5 (1%) 13 (35%) I(l9%) I* (2%) 0 
Sudden cardiac deaths 5 (6%) 5 (14%) 0 0 0 
No. of patients with VTlVF recurrence 24 (30%) 7 (19%) 6 (67%) I5 (28%) 2 (33%) 
Length of follow-up (mo) 26 22 39 86 39 
*Patient died of cancer. MI = myocardial infarction; RVD = right ventricular dysplasia: SMVT = sustained 
monomorphic ventricular tachycardia 
delayed afterdepolarizations (31) or the use of special elec- surgical, electrical or chemical ablative therapy is consid- 
trode catheters that record a monophasic action potential ered, but also allows the evaluation of the effect of pharma- 
resembling an intracellular recording (32). cologic or nonpharmacologic therapy (38). 
It is important to recognize not only the type, site of 
origin and mechanism of the arrhythmia but also its etiol- 
ogy. As shown in Table 2, the value of ventricular tachycar- 
dia/fibrillation as a prognostic indicator for cardiac death in 
patients with an old myocardial infarction is totally different 
from the value in patients who have arrhythmogenic right 
ventricular dysplasia or are without heart disease (so called 
idiopathic ventricular tachycardia or ventricular fibrillation). 
Similarly, the prognostic importance of advanced forms of 
ventricular arrhythmias has been well documented in ven- 
tricular hypertrophy (of all causes) and cardiomyopathy 
(33-35). 
Holter versus electropbysiologic study. An important 
question is which of the two methods (ambulatory ECG 
recording or an electrophysiologic study) provides the most 
accurate prediction of antiarrhythmic drug efficacy. The only 
available randomized comparison of the two methods (39) 
suggests that electrophysiologic study is better than Holter 
monitoring in predicting success of therapy. Limitations of 
this investigation include the small number of patients stud- 
ied and the use of nonstandardized drug therapy. A multi- 
center study (the Electrophysiologic Study Versus Electro- 
cardiographic Monitoring [ESVEM] trial) (40) involving a 
much larger number of patients is currently addressing this 
problem. It should be realized, however, that Holter moni- 
toring primarily registers the effect of an intervention on 
spontaneously occurring arrhythmias whereas the electro- 
physiologic study gives information on the effect on the 
substrate of the arrhythmia. Information from both tests is 
therefore frequently required to obtain optimal information 
on the response to therapy. 
Value and Limitations of Different 
Diagnostic Techniques 
Ambulatory electrocardiographic recordings. Several 
noninvasive and invasive tests are currently used in patients 
suffering from arrhythmias. The type, incidence, etiology 
and significance of an arrhythmia determine which diagnos- 
tic test or tests should be performed. That choice is also 
influenced by the preferred treatment (drugs, surgery, elec- 
trical ablation, pacing, and so forth). As pointed out by 
several investigators, frequently occurring arrhythmias can 
best be studied by 24 h ECG ambulatory (Holter) recordings. 
Such recordings can also give information about the role of 
the autonomic nervous system and the effect of therapeutic 
interventions (36). Unfortunately, however, 35% to 50% of 
patients with documented sustained ventricular tachycardia 
or ventricular fibrillation do not show complex arrhythmias 
on Holter monitoring (37). 
Invasive electropbysiologic study. Such a study is usually 
selected when the arrhythmia occurs infrequently and the 
somatic or psychologic consequences, or both, require in- 
formation as to the site of origin and the best therapeutic 
approach. An electrophysiologic study not only identifies the 
site of origin of the arrhythmia, which is essential when 
Signal-averaged electrocardiogram. This recording usu- 
ally shows late potentials in patients having a myocardial 
area of slow conduction as the basis for their reentrant 
ventricular tachycardia (41). The finding of late potentials 
does not establish the presence of a reentrant circuit but may 
only indicate an area of delayed activation. The prognostic 
significance of a ventricular late potential on the signal- 
averaged surface ECG as a marker for an increased inci- 
dence of life-threatening ventricular arrhythmias and sudden 
death is currently being investigated (42). It is less com- 
monly found in patients with spontaneous ventricular fibril- 
lation than in patients with spontaneous ventricular tachy- 
cardia (43). Controversies exist about the signal-processing 
techniques for detecting ventricular late potentials (44-46). 
We believe that more follow-up studies are needed to 
establish the true value (alone or in combination with other 
techniques, like the left ventricular ejection fraction) of the 
signal-averaged ECG to identify patients at high risk for the 
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Figure 2. Estimation of risk of sudden death based on the four 
clinical variables discussed in the text. As shown in this group of 200 
consecutive patients with a previous myocardial infarction (MI) 
develonine ventricular tachvcardia (VT) or ventricular fibrillation 
(VF), he; was a 6% incidence of dying suddenly within 2 years. 
NYHA = New York Heart Association classification for dyspnea. 
Figure 3. Estimation of risk of nonsudden cardiac death in the same 
patients as in Figure 2. The overall incidence of nonsudden cardiac 
death at 2 years was 9%. Abbreviations as in Figure 2. 
spontaneous occurrence of sustained ventricular tachycar- 
dia. 
Role of exercise testing. Exercise testing should not only 
be performed in patients with a history of exercise-related 
arrhythmias or to identify ischemia in a patient with an 
arrhythmia but also because induction of a sustained ven- 
tricular arrhythmia by exercise carries a poor prognosis. 
Exercise testing should always be performed when a patient 
is placed on an antiarrhythmic drug regimen because drugs, 
especially those slowing intraventricular conduction, may 
promote the occurrence of ventricular tachycardia during 
exercise (47,48). Exercise testing is therefore an essential 
investigation to identify a possible proarrhythmic effect of a 
drug (49). 
Risk Stratification of Arrhythmias 
As already discussed (Table 2) etiology plays an impor- 
tant role in the prognostic significance of an arrhythmia. But 
even within a seemingly homogeneous group such as that of 
patients developing monomorphic ventricular tachycardia or 
ventricular fibrillation outside the acute phase of myocardial 
infarction, marked differences in risk can be (and have to be) 
recognized. 
Risk factors for cardiac death. Figures 2 and 3 present 
four questions related to the clinical history that can be of 
great help in assessing risk for nonsudden and sudden 
cardiac death in these patients (50). These questions are: 1) 
What is the New York Heart Association functional classi- 
fication exclusive of the arrhythmia? 2) Did the patient lose 
consciousness during the arrhythmia? 3) Did the first episode 
of ventricular tachycardia or ventricular fibrillation occur 
between day 3 to day 60 after myocardial infarction, or later? 
4) Has the patient had more than one prior myocardial 
infarction? 
We found in 200 consecutive patients with ventricular 
tachycardia or fibrillation after a myocardial infarction (Fig. 
2) that with these questions we could recognize patients with 
a very low chance of dying suddenly (those not losing 
consciousness during the first episode of their spontaneous 
ventricular tachycardia or fibrillation and having the arrhyth- 
mia >2 months after their myocardial infarction). In con- 
trast, the question also identified patients who had a 25% 
chance of sudden cardiac death within 2 years (Fig. 2). 
Figure 3 shows that pump function is the most important 
discriminatorfor risk of nonsudden cardiac death in patients 
with ventricular tachycardia and ventricular fibrillation after 
a myocardial infarction. Figure 4 indicates how the total 
score of the four variables from the clinical history influ- 
ences the risk for sudden and total cardiac death in the first 
2 years in patients whose first episode of ventricular tachy- 
arrhythmia occurs >3 days after a myocardial infarction. 
Figure 5 shows (using the same variables as in Figures 2 to 4) 
that, in contrast to survival, recurrences of ventricular 
tachycardia are not related to the score of the four questions 
from the clinical history. 
Risk of fatal arrhythmia after infarction without spontane- 
ous arrhythmia. All patients shown in Figures 2 to 5 entered 
the study after they had had a spontaneous episode of 
ventricular tachycardia and ventricular fibrillation after a 
myocardial infarction. A much more difficult problem is to 
estimate risk of dying from an arrhythmia in the survivor of 
a myocardial infarction without a spontaneously occurring 
life-threatening ventricular arrhythmia. It has been recog- 
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Figure 4. Incidence of total cardiac death (0) and sudden cardiac 
death (A) in relation to the total score of four clinical variables in 200 
patients (pts) with ventricular tachycardia (169 patients) or ventric- 
ular fibrillation (VF) (31 patients) after myocardial infarction (MI). 
The four clinical variables are listed in the upper right corner of the 
figure. As shown, depending on the number of variables present, 
marked differences exist in sudden and total cardiac death after 2 
years of follow-up. 
nized that the finding of complex forms of ventricular 
arrhythmia, primarily runs of nonsustained ventricular 
tachycardia on ambulatory ECG monitoring, is associated 
with an increased risk of sudden cardiac death (51-54). 
Similar observations have been made in patients with hyper- 
trophic or dilated cardiomyopathy (55-57). Additional im- 
pairment of left ventricular function leads to an exponential 
increase in incidence of sudden death (58). 
Apart from information about spontaneous ventricular 
arrhythmias on ambulatory ECG monitoring, pump function 
(usually obtained by measuring left ventricular ejection 
fraction) and reversible myocardial ischemia at exercise 
testing, the use of other techniques has been suggested to 
improve stratification of risk for a life-threatening arrhyth- 
mia after a myocardial infarction. Richards et al. (59) indi- 
cated that induction of a “slow” ventricular tachycardia 
(shortly after myocardial infarction, cycle length ~230 ms) 
by programmed stimulation of the heart was a strong pre- 
dictor of sudden death or spontaneous ventricular tachycar- 
dia in the first year after a myocardial infarction. This finding 
was independent of left ventricular ejection fraction and was 
of more value than the signal-averaged ECG. There is 
discussion, however, about the value of programmed elec- 
trical stimulation in risk stratification after myocardial infarc- 
tion (60-63). This factor and the risks and costs of the test do 
100 
1 
-I 
8o cl TOTAL MORTALITY 
-cl SUDDEN DEATH 
60- Kll CARDIAC DEATH 
RECURRENT VENTRICULAR TACHYCARDIA 
40 
1 
I: i n,,l 
o-1 2-4 
NUMBER OF CLINICAL VARIABLES 
N=l41 N-49 
Figure 5. Risk of dying suddenly and nonsuddenly and of recurrent 
episodes of ventricular tachycardia in relation to the presence of the 
same four variables shown in Figure 4. Recurrences of ventricular 
tachycardia were at least as common in patients with no or one 
variable as in patients having two to four variables. 
not support its use for routine risk stratification of patients 
recovering from an acute myocardial infarction. 
Value, Limitations and Costs of the Different 
Therapeutic Options 
Table 3 shows the different therapeutic modes currently 
available in relation to their effect on the arrhythmia sub- 
strate, costs, required expertise, long-term efficacy and side 
effects, 
Antiarrhythmic Drugs 
Currently available antiarrhythmic drugs do not destroy 
the substrate of the arrhythmia. They may change the 
electrophysiologic properties like conduction velocity or 
refractory period duration within the substrate or may pre- 
vent the trigger of arrhythmia-like ventricular premature 
beats or sudden changes in heart rate. In Europe, approxi- 
mately 50 different antiarrhythmic drugs are available. All of 
these drugs differ in their effects-their half-life (Fig. 6), 
resorption, breakdown, excretion, active metabolites, side 
effects, and so forth. To make the situation even more 
complicated, their electrophysiologic effects may be related 
to heart rate and may be different in healthy and diseased 
cardiac tissue. 
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Table 3. Current Modes of Therapy of Arrhythmias in Relation to Effect on Arrhythmia Substrate, Costs, Required Expertise, 
Long-Term Efficacy and Side Effects 
Drugs Surgery 
Electrical 
Ablation 
Chemical 
Ablation 
Pacing Dev/ 
Defib 
Arrhythmia substrate removed 
costs 
Specialized center 
Long-term efficacy 
Side effects 
No 
Low 
? 
Yes 
Yes 
Yes 
High 
Required 
Yes 
10 to 15% operative 
mortality in VT 
Yes 
Moderate 
Required 
7 
Myocardial 
damage 
Yes 
Moderate 
Required 
? 
Myocardial 
damage 
No 
Moderately high 
Required 
Yes 
Psychological 
Abl = ablation; Defib = implantable defibrillator; Pacing Dev = implantable pacing device; VT = ventricular tachycardia. 
The CAST study: role of class Ic drugs. The interim 
results of the Cardiac Arrhythmia Suppression Trial (CAST) 
study (64) highlight some of the problems with antiarrhyth- 
mic drug therapy. The intention of the CAST study was to 
answer the question: Does suppression of ventricular ec- 
topic activity after a myocardial infarction result in better 
outcome? The CAST study was based on the evidence 
(51-54) that ventricular ectopic activity after myocardial 
infarction worsens prognosis. Previous studies (65-67) have 
failed to show benefit of treatment by antiarrhythmic drugs, 
with the exception of beta-adrenergic blocking agents, but in 
those studies patients were not selected after it had been 
shown that the antiarrhythmic drug was able to markedly 
reduce ventricular ectopic activity. 
Although complete data are not available, preliminary 
results indicate that administration of flecainide and encain- 
ide (after having been shown to suppress ventricular ectopic 
activity) resulted in a higher arrhythmic death rate than that 
of patients receiving placebo. What caused this unfavorable 
effect? A few possible mechanisms have to be considered. 
First, some patients, after administration of a class Ic drug, 
show widening of the QRS complex on exercise, indicating 
PROCAINAYIDE 
PROPAFENONE 
MEXILETINE 
ACTING) 
slowing in intraventricular conduction with increasing heart 
rate. This event may have favored the induction of ventric- 
ular tachycardia (48,49). Second, Nattel et al. (68) observed 
some years ago in dogs, that pretreatment with an antiar- 
rhythmic drug slowing conduction (aprindine) followed by 
coronary artery occlusion resulted in a much higher inci- 
dence of life-threatening ventricular arrhythmias than that of 
dogs having coronary obstruction without previous antiar- 
rhythmic drug treatment. The investigators found marked 
slowing in conduction in the ischemic area in the dogs 
pretreated with aprindine. These observations suggest the 
possibility that, during an ischemic episode the occurrence 
of ventricular arrhythmias is facilitated in patients with 
coronary artery disease treated with an antiarrhythmic drug 
that slows conduction. 
Third, class Ic drugs (like Jiecainide and encainide) slow 
conduction velocity without affecting the duration of the 
refractory period of myocardial tissue. Figure 7, which is 
based on observations by Brugada et al. (69) in an animal 
model of ventricular tachycardia, shows that, depending on 
the length of the reentrant circuit, slowing in conduction 
velocity without lengthening of the refractory period may 
Figure 6. The mean half-life of several cur- 
rently available antiarrhythmic drugs; marked 
differences exist among these drugs. Half-life is 
only one property of the drug. There are also 
differences in pharmacokinetics, breakdown, 
excretion, active metabolites, side effects, and 
so forth. 
3 6 9 12 15 18 21 24 HOURS 
HALF LIFE OF ANTIARRHYTHMIC DRlKiS 
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wL=cvxNP: 10 CM/S X 250 MS = 2.5 CM 7.5 CM/S X 250 MS = 1.66 CM 
ClFlcUlT LENGTH: 4CM 4CM 
EXIT ACTIVATED: 150/m 2 X 113/MH = 226iMIN 
Figure 7. Possible mechanism of acceleration in rate of tachycardia 
by a drug that slows conduction velocity but does not prolong the 
refractory period. Panel A shows a reentrant circuit with a length of 
4 cm and a single exit point. The wave length (WL) of the circulating 
impulse (the product of conduction velocity [CV] and the refractory 
period [RV]) measures 10 cm/s x 250 ms = 2.5 cm. Each minute, 
150 impulses will leave the exit point. Panel B shows the situation 
after the administration of a drug (like a class Ic drug) that slows 
conduction without lengthening the refractory period (RP) within 
the circuit. The wave length (WL) now measures 7.5 cm/s x 200 ms 
= 1.88 cm. This means that two consecutive impulses can fit within 
the circuit of 4 cm. Each minute 2 x 133 = 226 impulses will reach 
the exit point of the circuit. 
result in the situation that two (instead of one) circulating 
impulses can fit within one reentrant circuit. A possible 
clinical example is given in Figure 8. Theoretically, there- 
fore, after administration of a class Ic drug, acceleration of a 
ventricular ectopic rhythm (possibly leading to sudden 
death) may occur if a ventricular reentrant circuit is present 
after myocardial infarction. 
Our group (62) has demonstrated that ventricular reen- 
trant circuits are present in about 40% of patients studied by 
programmed stimulation of the heart shortly after myocar- 
dial infarction. The incidence of such a circuit did not differ 
in patients with or without documented episodes of nonsus- 
tained ventricular tachycardia. A reentrant circuit (as dem- 
onstrated by the reproducible initiation of sustained ventric- 
ular tachycardia during programmed stimulation) was 
present in 93% of patients with documented spontaneous 
episodes of sustained ventricular tachycardia. These obser- 
vations suggest that in a large number of patients a possible 
ventricular reentrant circuit is present after myocardial 
infarction independent of the spontaneous occurrence of 
ventricular tachycardia. Administration of an agent slowing 
conduction velocity without lengthening the refractory pe- 
riod may under those circumstances facilitate (as shown in 
Fig. 7 and 8) the occurrence of a more rapid ventricular 
tachycardia possibly leading to sudden cardiac death. 
Implications. The marked differences in properties 
among antiarrhythmic drugs can make the selection of such 
drugs very difficult. This is reason for us to stress that 1) a 
physician treating arrhythmias should be really knowledge- 
able about a few antiarrhythmic drugs (and restrict himself 
I 
Figure 8. Possible clinical example of the situation in Figure 7. 
During intravenous administration of a class Ic drug a sudden 
acceleration in rate of ventricular tachycardia is observed without 
change in QRS configuration. The change in RR interval 500 ms to 
380 ms can be explained by assuming a change from one to two 
circulating impulses within one reentrant circuit. Other possible 
mechanisms are a sudden change from a larger to a smaller reentrant 
circuit using the same exit point. 
or herself to those drugs); and 2) high risk patients should be 
referred to a center with expertise and equipment for treating 
arrhythmias. 
Surgery 
Identification of the site of origin of an arrhythmia (as in 
atria1 or ventricular tachycardia) or the essential component 
in a tachycardia pathway (like the accessory AV pathway in 
the Wolff-Parkinson-White syndrome) was the basis for the 
development of new surgical methods for treating arrhyth- 
mias. At present, many different types of tachycardias can 
be approached surgically. In some types, surgical treatment 
is still in an experimental phase (as in atria1 flutter or atria1 
fibrillation), in others (like the Wolff-Parkinson-White syn- 
drome, AV node tachycardia and ventricular tachycardia) 
their value is well established (7C78). As pointed out in 
Table 3, by removing, isolating or interrupting the arrhyth- 
mia substrate, surgery offers curative treatment. It can only 
be done, however, in specialized centers having expertise in 
localizing the arrhythmia. Operative risk depends on the 
type of arrhythmia. Perioperative mortality varies from 10% 
to 15% for ventricular tachycardia to almost zero for the 
Wolff-Parkinson-White syndrome (77,78). 
In ventricular tachycardia, operative mortality and long- 
1424 WELLENS AND BRUGADA JACC Vol. 14, No. 6 
TREATMENT OF CARDIAC ARRHYTHMIAS November 15, 1989:1417-28 
term outcome can be improved by careful selection of 
patients. Van Hemel et al. (79) recently reported on the use 
of a left ventricular segmental wall motion score for that 
purpose. They suggested nonsurgical therapy if less than 
three of nine segments of the left ventricle showed normal 
motion or slight hypokinesia. 
Costs ofsurgery are high because of the detailed electro- 
physiologic studies required before, during and after opera- 
tion, but as shown for the Wolff-Parkinson-White syndrome, 
surgical treatment can be cost effective (80). 
Electrical Ablation or Fulguration 
An electrical shock can destroy tissue in which an ar- 
rhythmia originates or a pathway that plays a role in con- 
duction of the cardiac impulse. At present, it has been used 
successfully to interrupt conduction in the His bundle and 
accessory AV pathways and to treat patients with atrial, AV 
node and ventricular tachycardia (81-86). Its use for treating 
patients with atria1 flutter is under investigation (87). Again, 
as with surgery, this treatment requires a specialized center. 
Good long-term results have been obtained in His bundle 
ablation. Because of a smaller series of patients long-term 
outcome is not yet clear for the different types of tachycardia 
treated with electrical ablation. Use of other techniques like 
radiofrequency and laser ablation is being studied (88,89). 
Chemical Ablation 
After experiments by Inoue et al. (90) that showed the 
possibility of destroying arrhythmogenic myocardial tissue 
by injecting chemicals into the coronary artery supplying 
that area, arrhythmias have been successfully treated in 
humans by transcoronary chemical ablation of the arrhyth- 
mia substrate (91). In patients with ventricular tachycardia 
not responding to or not suitable for pharmacologic or 
nonpharmacologic intervention, selective injection of alco- 
hol into the coronary artery branch supplying the arrhyth- 
mogenic area resulted in cure of the arrhythmia. The tech- 
nique, which requires expertise in both “angiographic and 
electrophysiologic mapping” of the site of origin of the 
arrhythmia, results in a small amount of myocardial damage. 
We have also applied chemical ablation of AV node conduc- 
tion by selective injection of alcohol in the AV node coro- 
nary artery in patients in whom electrical ablation of AV 
conduction was unsuccessful. At present, the technique 
should be considered experimental and long-term results are 
awaited. 
Pacing and Defibrillation 
Indications. The value of antitachycardia pacemakers in 
the management of supraventricular and ventricular reen- 
trant tachycardia has been well demonstrated (92-95). Anti- 
tachycardia pacing may be the therapy of choice in patients 
who do not respond to or cannot tolerate drugs, patients who 
do not take the prescribed medication, are not suited for or 
refuse surgery or are not able to tolerate prolonged episodes 
of tachycardia because of the development of cardiac failure, 
angina pectoris or dizziness. Patients may prefer treatment 
with a small reliable pacemaker instead of the long-term 
intake of antiarrhythmic drugs with possible side effects and 
accumulating expense. Fully automatic pacemakers may 
terminate tachycardia so rapidly that the arrhythmia is not 
noticed or is experienced only as a premature beat. 
Role of pacing. In recent years, research has been di- 
rected to identifying a single and simple mode of pacing that 
terminates tachycardia rapidly and safely, irrespective of 
rate, site of origin and body position. We believe that such a 
“universal” pacing mode can best be achieved by giving 
premature stimuli during the tachycardia with adaptive coup- 
ling intervals and an automatically increasing number of 
stimuli (96). Termination of tachycardia by pacing, espe- 
cially at the ventricular level, carries the risk of tachycardia 
acceleration and ventricular fibrillation. In devices im- 
planted for pacing termination of ventricular tachycardia, a 
back-up defibrillation mode should therefore be imple- 
mented. 
The implantable automatic defibrillator. The value of the 
implantable automatic defibrillator in properly selected cases 
has been well documented (97-99). Candidates for implan- 
tation include patients with cardiac arrest, those with recur- 
rent symptomatic episodes of ventricular tachycardia de- 
spite drug therapy and those with syncope. Most patients 
have underlying coronary artery disease or cardiomopathy. 
A point of discussion is what should be considered an 
adequate antiarrhythmic trial before insertion of a defibril- 
lator is advised. Our own approach to this problem will be 
discussed later. 
The Practical Approach to Treatment 
The decision to treat or not to treat an arrhythmia should 
be based on answers to two questions. Is the patient symp- 
tomatic during the arrhythmia? Has the arrhythmia prognos- 
tic significance (either because of structural cardiac disease 
or because the arrhythmia will lead to cardiac damage as in 
incessant tachycardia)? Four answers are possible. 
1. The patient is symptomatic and the arrhythmia has 
prognostic significance. In these patients treatment of the 
arrhythmia is indicated. An example is the patient with 
sustained ventricular tachycardia and ventricular fibrillation 
after a previous myocardial infarction. Depending on the risk 
profile (Fig. 2 to 4) and after correction (as best as possible) 
of ischemia and pump failure, the patient with a small chance 
of dying suddenly is treated with an antiarrhythmic drug, 
preferably guided by results from programmed electrical 
stimulation of the heart. Inability to initiate a previously 
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inducible arrhythmia after drug therapy definitely predicts a 
reduced chance of spontaneous recurrences of ventricular 
tachycardia (100-102). 
There is a diflerence in opinion, however, on the effect of 
suppression of arrhythmia inducibility by drug therapy on 
the chance of dying suddenly (103-105). Therefore, in the 
patient with a high chance of an arrhythmic death (Fig. 2, 
left) in view of the poor outcome with antiarrhythmic drug 
treatment, nonpharmacologic treatment should be consid- 
ered in an early stage. If destruction or isolation of the 
arrhythmia substrate is not possible or too risky, an electri- 
cal device able to pace and defibrillate should be implanted. 
Another example of an arrhythmia that is symptomatic 
and of prognostic significance is found in the patient suf- 
feringfrom cardiomyopathy induced by a tachycardia. Typ- 
ically, the arrhythmia is incessant (it can be atria1 fibrillation, 
atria1 flutter, atria1 tachycardia, circus movement tachycar- 
dia using an accessory AV pathway with long conduction 
times or ventricular tachycardia) and cure of the arrhythmia 
is essential to interrupt a downhill course. 
2. The patient is symptomatic hut the arrhythmia has no 
prognostic significance. In this group we find patients who 
have a normal heart but arrhythmias leading to symptoms 
such as dizziness, syncope and dyspnea. Examples are the 
patients with circus movement tachycardia in the Wolff- 
Parkinson-White syndrome and the patient with idiopathic 
ventricular tachycardia. Treatment is selected depending on 
the incidence and severity of the arrhythmia and the age of 
the patient. A young patient with frequent episodes of circus 
movement tachycardia is preferably treated with surgical or 
electrical ablation of the accessory pathway, whereas a 
patient with idiopathic ventricular tachycardia should 
first receive antiarrhythmic drug therapy. In the symptom- 
atic patient having no additional heart disease care should be 
taken not to prescribe an antiarrhythmic drug that, because 
of proarrhythmic or other side effects, worsens the situation. 
3. The patient is asymptomatic hut the arrhythmia has 
prognostic significance. In this category we find patients with 
a complex ventricular arrhythmia after myocardial infarction 
or in the presence of cardiomyopathy, hypertensive heart 
disease or congestive heart failure. In these patients the 
emphasis should primarily be on correction (if possible) of 
the contributing factors shown in Figure 1. Apart from 
treatment with beta-blocking agents and the possible excep- 
tion of the use of amiodarone in hypertrophic cardiomyop- 
athy (106), no convincing evidence has been presented that 
suppression of the spontaneously occurring arrhythmias by 
antiarrhythmic drug therapy leads to a decrease in arrhyth- 
mic death. The value of nonpharmcologic antiarrhythmic 
therapy in these patients is not clear. 
4. The patient is asymptomatic and the arrhythmia has no 
prognostic significance. An example is the patient with a 
(complex) ventricular arrhythmia in the absence of structural 
heart disease. No antiarrhythmic treatment should be pre- 
scribed. 
It is clear that the approach described requires ability to 
perform reliable risk classification of the patient. As pointed 
out, this is possible in some patients (for example the patient 
with ventricular tachycardia/fibrillation after myocardial in- 
farction or the patient with hypertrophic cardiomyopathy) 
(106) but much more difficult or even impossible in others. 
The Future 
Better risk classification is one of the most important 
challenges of the “arrhythmology” of tomorrow. More 
precise and less costly methods are urgently needed. In risk 
classification, also, the role of the autonomic nervous system 
should be known better and methods to evaluate and correct 
abnormalities should be developed (107,108). It seems un- 
likely, in view of the different mechanisms of arrhythmias, 
that a universal antiarrhythmic drug will be developed. 
Because most clinically occurring arrhythmias seem to be 
based on a reentrant mechanism, the profile of an ideal 
antireentrant drug should include the ability to suppress 
triggering mechanisms, like premature beats, and to lengthen 
the refractory period of myocardial tissue without affecting 
conduction velocity. The drug should also prevent rate- 
related shortening of the refractory period of myocardial 
tissue, have anti-ischemic properties and reduce sudden 
oscillations in the balance of the autonomic nervous system. 
In addition, it should have a long half-life, no side effects and 
be inexpensive. 
Theoretically, by using molecular biologic techniques, 
agents could be developed that are site specific, selectively 
inactivating cells in the arrhythmogenic area. These fasci- 
nating new possibilities have recently been discussed by 
Zipes (2). In the absence of antiarrhythmic “miracle” drugs, 
increasing use will be made of electrical devices in the high 
risk patient. Smaller, less expensive units not requiring 
thoracotomy will become available. Last but not least, an 
important aspect in arrhythmia management will be its 
prevention. In acute myocardial infarction, thrombolytic 
therapy by reducing infarct size has resulted in a decrease of 
both spontaneous and inducible ventricular arrhythmias 
(109,110). Primary prevention of coronary heart disease 
should lead to a further decrease in serious arrhythmias in 
the future (Ill). 
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